Transgene SA (FRA:TGNA)

Market Cap	266.16M
Revenue (ttm)	7.58M
Net Income (ttm)	-36.78M
Shares Out	n/a
EPS (ttm)	-0.28
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	2,689
Open	0.9080
Previous Close	0.9120
Day's Range	0.9080 - 0.9080
52-Week Range	0.5500 - 1.4850
Beta	n/a
RSI	53.35
Earnings Date	Mar 27, 2026

About Transgene

Transgene SA, a biotechnology company, designs and develops therapeutic vaccines and oncolytic viruses for the treatment of cancer in France. It involved in developing TG4050, a therapeutic vaccine that is in Phase II clinical trial for the treatment of ovarian cancer, and head and neck cancers; TG4001, a therapeutic vaccine, which is in Phase II clinical trial for the treatment of human papillomavirus (HPV 16) positive cancers; TG6002, an oncolytic virus that is in Phase I/IIa clinical trial for the treatment of solid tumors, including gastroi...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1979
• Employees: 144
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: TGNA

Financial Performance

In 2024, Transgene's revenue was 6.35 million, a decrease of -19.58% compared to the previous year's 7.90 million. Losses were -33.97 million, 52.1% more than in 2023.